Oral rehydration salts (ORS) remain one of the most important interventions in pediatric healthcare, particularly in countries where diarrhoeal infections, unsafe drinking water and inadequate sanitation continue to affect childhood survival. According to UNICEF's July 2026 supply update, approximately 1.7 billion childhood diarrhoea episodes occur annually worldwide, creating demand for around 4 billion ORS sachets and 20 billion zinc tablets if all cases receive optimal treatment.
-
However, only 22% of children with diarrhoea currently receive combined ORS and zinc treatment.
-
This substantial treatment gap highlights the importance of expanding affordable pediatric rehydration products through public healthcare systems, pharmacies and community-based treatment programmes.
WHO's Updated Pediatric Treatment Guidelines Are Influencing Product Formulations
The World Health Organization's December 2024 guideline on managing pneumonia and diarrhoea in children up to 10 years has strengthened the clinical framework surrounding pediatric diarrhoea treatment. The recommendations include low-osmolarity ORS for children experiencing acute watery diarrhoea with dehydration, alongside oral zinc supplementation.
An important development involves the recommended zinc dosage. WHO suggests 5 mg daily for up to 14 days, with zinc gluconate identified as a better-tolerated formulation because of its improved vomiting profile. However, UNICEF's July 2026 update confirms that 5 mg tablets are not yet commercially available, so the established 20 mg daily dosage continues to be advised. These developments are influencing pharmaceutical formulation planning, product registration and the development of child-friendly treatment combinations.
UNICEF's Procurement Strategy Highlights the Scale of Pediatric ORS Requirements
-
Global healthcare procurement is becoming an important part of the oral rehydration salts industry. UNICEF has maintained ORS and zinc co-packaged products in its supply catalogue since 2014, while the combination was included in the WHO Essential Medicines List in 2019.
-
Its July 2026 update identifies approximately 50 million ORS sachets procured annually through UNICEF, substantially below the estimated worldwide requirement. UNICEF also works with certified manufacturers through long-term arrangements and competitive tenders, helping maintain product availability during emergencies and periods of supply disruption.
-
Manufacturers are increasingly required to consider different sachet sizes, formulation specifications and co-packaging configurations. Available product presentations include formulations designed for 200 ml, 500 ml, 750 ml and 1 litre of water, allowing procurement programmes to accommodate different clinical and distribution requirements.
The Child-Friendly Formulation Race Is Moving Beyond Basic Electrolyte Replacement
Product development is increasingly focused on making ORS easier for caregivers to administer and healthcare professionals to distribute. Flavoured and unflavoured formulations, clearly labelled sachets, improved dissolution characteristics and convenient packaging are gaining relevance in pediatric medicine distribution.
The combination of ORS with zinc is particularly important because the two treatments serve complementary purposes. ORS replaces fluids and electrolytes lost during diarrhoea, while zinc supplementation helps reduce the duration and severity of episodes. WHO reports that zinc supplementation can reduce diarrhoea duration by approximately 25% and stool volume by around 30%.
For pharmaceutical companies, the opportunity extends beyond manufacturing conventional powder sachets to developing reliable co-packaged products that support accurate dispensing and improved treatment adherence.
India's Primary Healthcare Network Creates a Significant Distribution Opportunity
India remains an important healthcare environment for pediatric ORS accessibility because of its extensive public health infrastructure, pharmaceutical manufacturing capabilities and continuing focus on childhood diarrhoeal disease management.
Primary healthcare centres, government hospitals, community health workers and retail pharmacies represent important channels for distributing essential rehydration products. During seasonal increases in gastrointestinal infections, access to properly manufactured ORS becomes particularly important for households with young children.
The WHO's India guideline publication also provides an important reference for strengthening clinical protocols and improving the management of childhood diarrhoea across different age groups. This creates opportunities for domestic manufacturers to support institutional procurement, essential medicine availability and geographically broader distribution.
You Can Freely Surf Our Latest Updated Report Here: https://www.24lifesciences.com/oral-rehydration-salt-for-children-market-14308
Child Survival Statistics Are Keeping Affordable Rehydration Products in Focus
-
The latest global child mortality estimates released in March 2026 provide further context for the importance of accessible pediatric treatments.
-
UNICEF reported that approximately 4.9 million children died before their fifth birthday in 2024, with diarrhoea among the major infectious causes of childhood mortality beyond the neonatal period.
-
Sub-Saharan Africa accounted for 58% of under-five deaths in 2024, while Southern Asia accounted for another 25%. These figures underline the importance of strengthening essential medicine distribution, particularly in countries where healthcare access, safe water and sanitation remain uneven.
-
For ORS manufacturers, public health institutions and pharmaceutical distributors, affordable rehydration products remain closely connected to broader child survival objectives.
Quality Assurance and Sustainable Manufacturing Are Becoming Procurement Priorities
ORS production involves relatively straightforward ingredients, but consistent manufacturing quality remains essential. Incorrect composition, inadequate moisture protection, packaging failures and inaccurate dilution instructions can compromise product reliability.
UNICEF identifies quality assurance, limited commercial incentives and unpredictable financing as important considerations in securing long-term supply. Its sustainable procurement approach is also incorporating environmental and social criteria into supplier evaluation.
Manufacturers capable of maintaining GMP-compliant production, dependable sourcing, accurate formulation and suitable packaging will remain important participants in institutional and retail supply networks.